Wednesday’s Midday Movers: Celldex (CLDX), Cameco (CCJ), TG Therapeutics (TGTX), Dynavax (DVAX), Inovio Pharmaceuticals (INO)

So far Wednesday, July 29, NASDAQ is up 1.03% and the S&P is up 1.94%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Celldex (CLDXResearch Report), Cameco (CCJResearch Report), TG Therapeutics (TGTXResearch Report), Dynavax (DVAXResearch Report) and Inovio Pharmaceuticals (INOResearch Report).

Celldex is down -9.42% in midday trading to $10.10. Shares opened today at $11.15. The company has a 52-week low of $1.50 and a 52-week high of $13.91. On the Street’s front, the average 12-month analyst price target for the stock is $17.00, marking a 52.47% potential upside from current levels. In a report issued on July 1, Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on CLDX, with a price target of $18.00, which represents a potential upside of 61% from where the stock is currently trading. Over the last 3 months, the insider sentiment on Celldex has been positive based on 7 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Cameco is down -9.23% in midday trading to $10.67. Shares opened today at $11.75. The company has a 52-week low of $5.30 and a 52-week high of $12.33. On the Street’s front, the average 12-month analyst price target for the stock is $12.45, marking a 5.96% potential upside from current levels. In a report issued on July 15, Raymond James analyst Brian MacArthur maintained a Buy rating on CCJ, with a price target of C$17.00, which represents a potential upside of 45% from where the stock is currently trading. Separately, on May 5, RBC’s Andrew Wong maintained a Hold rating on the stock and has a price target of C$15.00. Over the last 3 months, the insider sentiment on Cameco has been negative based on 23 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

TG Therapeutics is down -8.43% in midday trading to $19.00. Shares opened today at $20.75. The company has a 52-week low of $4.95 and a 52-week high of $24.76. On the Street’s front, the average 12-month analyst price target for the stock is $41.00, marking a 97.59% potential upside from current levels. In a report issued on June 17, H.C. Wainwright analyst Edward White maintained a Buy rating on TGTX, with a price target of $32.00, which represents a potential upside of 54% from where the stock is currently trading. Over the last 3 months, the insider sentiment on TG Therapeutics has been negative based on 14 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Dynavax is down -8% in midday trading to $7.93. Shares opened today at $8.62. The company has a 52-week low of $1.80 and a 52-week high of $12.44. On the Street’s front, the average 12-month analyst price target for the stock is $15.33, marking a 77.84% potential upside from current levels. In a report issued on July 23, Cowen analyst Phil Nadeau reiterated a Buy rating on DVAX, with a price target of $20.00, which represents a potential upside of 132% from where the stock is currently trading. Over the last 3 months, the insider sentiment on Dynavax has been positive based on 17 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Inovio Pharmaceuticals is down -7.62% in midday trading to $19.52. Shares opened today at $21.13. The company has a 52-week low of $1.92 and a 52-week high of $33.79. On the Street’s front, the average 12-month analyst price target for the stock is $22.00, marking a 4.12% potential upside from current levels. In a report issued on July 20, H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on INO. Separately, on July 1, Roth Capital’s Jonathan Aschoff downgraded the stock to Sell and has a price target of $11.00. Over the last 3 months, the insider sentiment on Inovio Pharmaceuticals has been negative based on 26 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.